Tirelizumab
Sponsors
The First Affiliated Hospital of Zhengzhou University, Tianjin Medical University Cancer Institute and Hospital, Eye & ENT Hospital of Fudan University, Sichuan Cancer Hospital and Research Institute, Fudan University
Conditions
Adjuvant TherapyColon CancerEsophageal Squamous Cell CarcinomaGastric CancerImmunotherapyMSI-HNasopharyngeal CarcinomaPFS
Phase 2
Study of Perioperative Chemotherapy Combined With Tislelizumab and Trastuzumab in the Treatment of GC/EGC
NCT04819971
Start: 2021-12-01End: 2025-12-31Target: 67Updated: 2023-04-25
Immunotherapy Versus Chemotherapy as Adjuvant Therapy for Colon Cancer With MSI-H or POLE/ POLD1 Mutations
NCT04969029
Start: 2021-06-01End: 2024-12-31Target: 30Updated: 2021-07-20
Tirelizumab Plus Surgery vs Surgery Alone for Recurrent Nasopharyngeal Carcinoma
NCT05092217
Start: 2021-10-20End: 2024-10-20Target: 80Updated: 2021-10-25
Selected Chemotherapy Combined Immunotherapy Treated High Risk Patient After NCRT in Resected Locally Advanced ESCC
Active, not recruitingNCT05189730
Start: 2021-07-01End: 2027-01-31Target: 80Updated: 2025-11-20
Low Dose Decitabine in Combination With Tirelizumab Comparison of Tirelizumab in the First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma
NCT05638984
Start: 2023-01-01End: 2024-12-31Target: 60Updated: 2022-12-06
Efficacy and Safety of Tirelizumab Plus Chemotherapy Versus Chemotherapy Alone in Patients With Lymph Node Positive Gastric Cancer After Surgery
NCT05844371
Start: 2021-04-01End: 2024-04-01Target: 60Updated: 2023-05-06
Optimization of Treatment Strategy for Unresectable cN3 Esophageal Squamous Cell Carcinoma
RecruitingNCT06122493
Start: 2022-11-01End: 2026-11-01Target: 48Updated: 2023-11-08
The Efficacy and Safety of Utidelone Plus Tirelizumab and Bevacizumab for Advanced or Metastatic Triple-negative Breast Cancer (UTILIZABLE) ：Single-arm, Prospective, Open Clinical Study
RecruitingNCT06125080
Start: 2023-10-30End: 2026-10-30Target: 78Updated: 2023-11-09